Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 11/20 | 0.79 |
| ▸ | HSPD1 | P10809 | 4/20 | 0.71 |
| ▸ | HSPE1 | P61604 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24438031 | 1.00 | CTSD (0.79) | CTSDHSPD1HSPE1MAPTGAA | |
| SCHEMBL24118857 | 0.91 | HSPD1 (0.78) | CTSDHSPD1HSPE1MAPTGAA | |
| SCHEMBL24118859 | 0.91 | HSPD1 (0.79) | CTSDHSPD1HSPE1MAPTGAA | |
| SCHEMBL331402 | 0.88 | CTSD (0.80) | CTSDHSPD1HSPE1MAPTGAA | |
| SCHEMBL24438030 | 0.87 | CTSD (0.77) | CTSDHSPD1HSPE1TMPRSS4 | |
| SCHEMBL29655142 | 0.87 | CTSD (0.73) | CTSDHSPD1HSPE1MAPTPOLB | |
| SCHEMBL24438037 | 0.87 | CTSD (0.73) | CTSDHSPD1HSPE1MAPTPOLB | |
| SCHEMBL24118877 | 0.84 | CTSD (0.72) | CTSDHSPD1HSPE1MAPTGAA | |
| SCHEMBL24118858 | 0.83 | HSPD1 (1.00) | CTSDHSPD1HSPE1MAPTGAA | |
| SCHEMBL24118874 | 0.82 | HSPD1 (1.00) | CTSDHSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406831-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY | 2023-12-21 | — | — | US | disclosed |
| EP-4243799-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | The Trustees of Indiana University (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022103572-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406831-A1 | COMPOUNDS AND METHODS OF INHIBITING BACTERIAL CHAPERONIN SYSTEMS | HSP90B1, HSPBP1, HSP90AB1 | CTSD 2648/4885HSPD1 10/4885HSPE1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.